Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009923
Filing Date
2025-05-13
Accepted
2025-05-13 15:22:08
Documents
53
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 499011
2 EX-31.1 ex31-1.htm EX-31.1 18841
3 EX-31.2 ex31-2.htm EX-31.2 19872
4 EX-32.1 ex32-1.htm EX-32.1 9439
  Complete submission text file 0001641172-25-009923.txt   3356003

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ptix-20250331.xsd EX-101.SCH 27652
6 XBRL CALCULATION FILE ptix-20250331_cal.xml EX-101.CAL 34981
7 XBRL DEFINITION FILE ptix-20250331_def.xml EX-101.DEF 145550
8 XBRL LABEL FILE ptix-20250331_lab.xml EX-101.LAB 295761
9 XBRL PRESENTATION FILE ptix-20250331_pre.xml EX-101.PRE 228788
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 353532
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12555 | Film No.: 25939431
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)